At Friday's meeting of the WTO's Dispute Settlement Body (DSB), panels were established in two complaints brought against China by the EU, related to allegations about China's trade restrictions imposed on Lithuania and about restrictions on EU companies going to a foreign court to

After the failure by Pfizer and the Chinese government to reach an agreement on including COVID medicine Paxlovid in the state health insurance plan, there are some discussions in China on whether compulsory licensing is justified as cases are surging in the nation.

Earlier this year, the EU requested consultations with China at the WTO on two separate matters, related to allegations about China's trade restrictions imposed on Lithuania and about restrictions on EU companies going to a foreign court to protect and use their patents. Today, the EU announced that

In the annual report of the U.S.-China Economic and Security Review Commission issued yesterday, the Commission assessed and made recommendations on the issue of "anti-suit injunctions" issued by Chinese courts to enforce patents.

China's National Intellectual Property Administration (NIPA) updated the lists of demonstration and pilot cities for intellectual property rights (IPR) protection, part of its effort to enhance IPR protection and promote IP.

China's National Intellectual Property Administration (NIPA) recently ruled on two patent infringement disputes, the first of its kind under the agency's new authority to review major patent disputes.

Last week, the UK Department for Business, Energy & Industrial Strategy published a notice of final order that, based on national security concerns, blocked a Chinese company from licensing vision sensing technology from a UK university.